BRPI0816221A2 - Forma cristalina 1 da 2-((r)-2-metilpirrolidin-2-ol)-1h-benzimidazol-4-carbox amida - Google Patents

Forma cristalina 1 da 2-((r)-2-metilpirrolidin-2-ol)-1h-benzimidazol-4-carbox amida

Info

Publication number: BRPI0816221A2
Authority: BR; Brazil
Prior art keywords: methylpyrrolidin; benzimidazol; carboxamide; crystalline form; crystalline
Prior art date: 2007-10-12

Application number

BRPI0816221-2A

Other languages

English (en)

Inventor

Lawrence Kolaczkowski

Original Assignee

Abbott Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-12

Filing date

2008-10-10

Publication date

2015-06-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40210712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0816221(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-10-10 Application filed by Abbott Lab filed Critical Abbott Lab

2015-06-16 Publication of BRPI0816221A2 publication Critical patent/BRPI0816221A2/pt

2015-09-22 Publication of BRPI0816221A8 publication Critical patent/BRPI0816221A8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BRPI0816221A 2007-10-12 2008-10-10 forma cristalina 1 da 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida BRPI0816221A8 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US97964307P	2007-10-12	2007-10-12
PCT/US2008/079441 WO2009049111A1 (en)	2007-10-12	2008-10-10	2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1

Publications (2)

Publication Number	Publication Date
BRPI0816221A2 true BRPI0816221A2 (pt)	2015-06-16
BRPI0816221A8 BRPI0816221A8 (pt)	2015-09-22

Family

ID=40210712

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0816221A BRPI0816221A8 (pt)	2007-10-12	2008-10-10	forma cristalina 1 da 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida

Country Status (28)

Country	Link
US (4)	US8372987B2 (pt)
EP (2)	EP2722046B1 (pt)
JP (4)	JP2011500589A (pt)
KR (2)	KR20100090769A (pt)
CN (2)	CN101821270A (pt)
AU (1)	AU2008310781B2 (pt)
BR (1)	BRPI0816221A8 (pt)
CA (2)	CA2696424C (pt)
CO (1)	CO6280493A2 (pt)
CR (1)	CR11368A (pt)
DK (1)	DK2722046T3 (pt)
DO (1)	DOP2010000099A (pt)
EC (1)	ECSP10010150A (pt)
ES (1)	ES2620299T3 (pt)
GT (1)	GT201000080A (pt)
MX (1)	MX350019B (pt)
MY (1)	MY156691A (pt)
NZ (1)	NZ583209A (pt)
PA (1)	PA8798401A1 (pt)
PH (1)	PH12012501636A1 (pt)
PL (1)	PL2722046T3 (pt)
PT (1)	PT2722046T (pt)
RU (2)	RU2476434C2 (pt)
SG (1)	SG185297A1 (pt)
TW (1)	TWI422588B (pt)
UA (2)	UA101961C2 (pt)
WO (1)	WO2009049111A1 (pt)
ZA (1)	ZA201002090B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2696423A1 (en)	2007-10-12	2009-04-16	Guidong Zhu	2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 2
RU2476434C2 (ru)	2007-10-12	2013-02-27	Эбботт Лэборетриз	Кристаллическая форма 1 2-((r)-2-метилпирролидин-2-ил)-1н-бензимидазол-4-карбоксамида
TW201702218A (zh)	2014-12-12	2017-01-16	美國杰克森實驗室	關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
CN105130961B (zh) *	2015-08-06	2018-02-16	苏州晶云药物科技有限公司	Abt‑888的晶型b及其制备方法和应用
CN106995436A (zh) *	2016-01-25	2017-08-01	重庆医药工业研究院有限责任公司	一种维利帕尼晶型a及其制备方法
US20190092756A1 (en) *	2016-03-09	2019-03-28	Crystal Pharmatech Co., Ltd.	Crystalline form a of 2-[(2r)-2-methyl-2-pyrrolidyl]-1h-benzimidazole-7-carboxamide dihydrochloride and preparation method thereof
EP3275434B1 (en)	2016-07-27	2020-08-26	Sandoz Ag	An extended release oral dosage form

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ20022332A3 (cs) *	2000-01-07	2003-01-15	Transform Pharmaceuticals, Inc.	Sestava vzorků
EP1298125A1 (en) *	2001-09-26	2003-04-02	Aventis Pharma S.A.	Substituted benzimidazole compounds and their use for the treatment of cancer
TWI375673B (en) *	2005-04-11	2012-11-01	Abbott Lab	1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
CA2696423A1 (en) *	2007-10-12	2009-04-16	Guidong Zhu	2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 2
RU2476434C2 (ru)	2007-10-12	2013-02-27	Эбботт Лэборетриз	Кристаллическая форма 1 2-((r)-2-метилпирролидин-2-ил)-1н-бензимидазол-4-карбоксамида

2008
- 2008-10-10 RU RU2010116397/04A patent/RU2476434C2/ru not_active IP Right Cessation
- 2008-10-10 MY MYPI2010001318A patent/MY156691A/en unknown
- 2008-10-10 NZ NZ583209A patent/NZ583209A/en not_active IP Right Cessation
- 2008-10-10 PA PA20088798401A patent/PA8798401A1/es unknown
- 2008-10-10 JP JP2010529063A patent/JP2011500589A/ja active Pending
- 2008-10-10 EP EP14151089.1A patent/EP2722046B1/en active Active
- 2008-10-10 SG SG2012075909A patent/SG185297A1/en unknown
- 2008-10-10 AU AU2008310781A patent/AU2008310781B2/en not_active Ceased
- 2008-10-10 ES ES14151089.1T patent/ES2620299T3/es active Active
- 2008-10-10 CA CA2696424A patent/CA2696424C/en active Active
- 2008-10-10 PT PT141510891T patent/PT2722046T/pt unknown
- 2008-10-10 UA UAA201005713A patent/UA101961C2/ru unknown
- 2008-10-10 CN CN200880111619A patent/CN101821270A/zh active Pending
- 2008-10-10 KR KR1020107010181A patent/KR20100090769A/ko not_active Ceased
- 2008-10-10 DK DK14151089.1T patent/DK2722046T3/en active
- 2008-10-10 CN CN201510450981.4A patent/CN105367554A/zh active Pending
- 2008-10-10 EP EP08838001A patent/EP2212327A1/en not_active Ceased
- 2008-10-10 MX MX2010003772A patent/MX350019B/es active IP Right Grant
- 2008-10-10 CA CA3006332A patent/CA3006332A1/en not_active Abandoned
- 2008-10-10 PL PL14151089T patent/PL2722046T3/pl unknown
- 2008-10-10 UA UAA201300752A patent/UA113277C2/uk unknown
- 2008-10-10 PH PH1/2012/501636A patent/PH12012501636A1/en unknown
- 2008-10-10 WO PCT/US2008/079441 patent/WO2009049111A1/en not_active Ceased
- 2008-10-10 US US12/248,972 patent/US8372987B2/en not_active Expired - Fee Related
- 2008-10-10 BR BRPI0816221A patent/BRPI0816221A8/pt not_active IP Right Cessation
- 2008-10-10 KR KR1020167008506A patent/KR20160039312A/ko not_active Withdrawn
- 2008-10-13 TW TW097139239A patent/TWI422588B/zh not_active IP Right Cessation
2010
- 2010-03-24 ZA ZA2010/02090A patent/ZA201002090B/en unknown
- 2010-04-08 DO DO2010000099A patent/DOP2010000099A/es unknown
- 2010-04-09 GT GT201000080A patent/GT201000080A/es unknown
- 2010-04-14 CR CR11368A patent/CR11368A/es unknown
- 2010-04-27 CO CO10049261A patent/CO6280493A2/es not_active Application Discontinuation
- 2010-05-03 EC EC2010010150A patent/ECSP10010150A/es unknown
2012
- 2012-11-08 RU RU2012147692/04A patent/RU2012147692A/ru not_active Application Discontinuation
2013
- 2013-01-07 US US13/735,190 patent/US20130123317A1/en not_active Abandoned
- 2013-09-27 US US14/039,479 patent/US8835647B2/en active Active
2014
- 2014-07-10 JP JP2014142248A patent/JP2014237659A/ja active Pending
- 2014-08-12 US US14/457,866 patent/US9580410B2/en not_active Expired - Fee Related
2016
- 2016-11-11 JP JP2016220220A patent/JP2017071618A/ja active Pending
2018
- 2018-09-07 JP JP2018167564A patent/JP2019001811A/ja active Pending

Also Published As

Publication number	Publication date
DK2722046T3 (en)	2017-03-20
CA3006332A1 (en)	2009-04-16
PH12012501636A1 (en)	2015-07-10
US20130123317A1 (en)	2013-05-16
KR20160039312A (ko)	2016-04-08
RU2476434C2 (ru)	2013-02-27
RU2012147692A (ru)	2014-05-20
JP2019001811A (ja)	2019-01-10
ES2620299T3 (es)	2017-06-28
BRPI0816221A8 (pt)	2015-09-22
TWI422588B (zh)	2014-01-11
JP2014237659A (ja)	2014-12-18
US20140024838A1 (en)	2014-01-23
CA2696424A1 (en)	2009-04-16
KR20100090769A (ko)	2010-08-17
ZA201002090B (en)	2011-11-30
CA2696424C (en)	2018-07-10
DOP2010000099A (es)	2017-04-30
PL2722046T3 (pl)	2017-06-30
CR11368A (es)	2010-10-25
GT201000080A (es)	2012-04-03
TW200932747A (en)	2009-08-01
UA113277C2 (xx)	2017-01-10
EP2722046B1 (en)	2016-12-21
MX2010003772A (es)	2010-04-21
US8835647B2 (en)	2014-09-16
MX350019B (es)	2016-12-09
US20090099245A1 (en)	2009-04-16
JP2011500589A (ja)	2011-01-06
ECSP10010150A (es)	2010-06-29
PA8798401A1 (es)	2009-05-15
US8372987B2 (en)	2013-02-12
CN105367554A (zh)	2016-03-02
UA101961C2 (xx)	2013-05-27
EP2722046A1 (en)	2014-04-23
AU2008310781A1 (en)	2009-04-16
EP2212327A1 (en)	2010-08-04
RU2010116397A (ru)	2011-11-20
WO2009049111A1 (en)	2009-04-16
MY156691A (en)	2016-03-15
AU2008310781B2 (en)	2013-03-28
NZ583209A (en)	2012-06-29
JP2017071618A (ja)	2017-04-13
US20150148392A1 (en)	2015-05-28
CO6280493A2 (es)	2011-05-20
PT2722046T (pt)	2017-03-15
CN101821270A (zh)	2010-09-01
US9580410B2 (en)	2017-02-28
SG185297A1 (en)	2012-11-29

Publication	Publication Date	Title
BRPI0915714A2 (pt)	2015-10-27	forma cristalina de posaconazol
DK2262793T3 (da)	2012-10-15	Krystallinske former af nilotinib-hci
BRPI0922904A2 (pt)	2018-05-29	"compostos"
BRPI0913806A2 (pt)	2015-10-20	"composição"
BRPI1015540A2 (pt)	2019-09-24	''composto de 1-cianoetil-heterociclilcarboxamida substituídos 750''
EP2298750A4 (en)	2012-04-25	NOVEL ISOXAZOLE DERIVATIVE
DK2214646T3 (da)	2021-10-04	Dendrimers for sustained release of compounds
EP2280916A4 (en)	2014-07-23	HYDROCHLORFLUOROLEFINZUSAMMENSETZUNGEN
DK2264042T3 (da)	2012-08-20	Mikronisering af polyoler
EP2147437A4 (en)	2015-01-14	SEEDING REPLICATION
BRPI1012004A2 (pt)	2016-05-10	"forma farmacêutica"
DK2185567T3 (da)	2011-05-16	Substituerede bicyclolactam-forbindelser
HRP20170222T1 (hr)	2017-04-07	Kristalni oblik karbamoil-cikloheksan derivata
SMAP200900055A (it)	2009-09-07	Chinazoline per l'inibizione di pdk1
SMAP200800059A (it)	2008-11-12	Chinazoline per l'inibizione di pdk1
EP2291078A4 (en)	2011-08-24	OXAZOLBENZIMIDAZOLDERIVATE
EP2491025A4 (en)	2013-01-23	AZAAZULENVERBINDUNGEN
ATE484507T1 (de)	2010-10-15	Heterocyclische spiroverbindungen
EP2279532A4 (en)	2011-07-27	OXAZOLBENZIMIDAZOLDERIVATE
EP2500932A4 (en)	2015-10-28	ADHESIVE COMPOSITION
BRPI0924746A2 (pt)	2016-01-26	"elemento delizante"
EP2432837A4 (en)	2013-05-08	ON REQUEST, CLEANABLE COMPOSITION FOR CORROSION INHIBITION
EP2318314A4 (en)	2016-03-09	SYNTHESIS OF CRYSTALLINE SILICONALUMINIUM PHOSPHATE
DK2262486T3 (da)	2013-03-25	Quetiapin sammensætning
BRPI0816221A2 (pt)	2015-06-16	Forma cristalina 1 da 2-((r)-2-metilpirrolidin-2-ol)-1h-benzimidazol-4-carbox amida

Legal Events

Date	Code	Title	Description
2015-09-15	B25A	Requested transfer of rights approved	Owner name: ABBVIE INC. (US)
2015-10-06	B25A	Requested transfer of rights approved	Owner name: ABBVIE BAHAMAS LTD. (US)
2016-12-20	B25A	Requested transfer of rights approved	Owner name: ABBVIE IRELAND UNLIMITED COMPANY (BM)
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-02-12	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-07-16	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-08-06	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 11A ANUIDADE.
2019-11-26	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2535 DE 06-08-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.